Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
Sign Up to like & getrecommendations! Published in 2023 at "Drug Metabolism and Disposition"
DOI: 10.1124/dmd.122.001096
Abstract: Taselisib (also known as GDC-0032) is a potent and selective phosphoinositide 3-kinase (PI3K) inhibitor that displays greater selectivity for mutant PI3Kα than wild-type PI3Kα. To better understand the absorption, distribution, metabolism, and excretion properties of… read more here.
Keywords: metabolism; taselisib; rats dogs; excretion taselisib ... See more keywords
Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-ct046
Abstract: Background:PIK3CA, a gene that encodes the α-isoform of the catalytic subunit of Class I PI3K (PI3Kα), is frequently mutated or amplified in solid tumors. Taselisib is an oral, potent, selective inhibitor of Class I PI3Kα,… read more here.
Keywords: pi3k; pik3ca mutated; solid tumors; taselisib ... See more keywords